Technology ID
TAB-3517
Small Molecule Inhibitors of LDHA for the Treatment of Glycolytic Cancers
E-Numbers
E-190-2016-0
Lead Inventor
Maloney, David
Lead IC
NCATS
Co-Inventors
Mott, Bryan
Yang, Shyh-Ming
Urban, Daniel
Jadhav, Ajit
Simeonov, Anton
Neckers, Leonard
Moore, William
Waterson, Alex
Rai Bantukallu, Ganesha
Brimacombe, Kyle
Christov, Plamen
Dang, Chi
Darley-Usmar, Victor
Hall, Matthew
Hu, Xin
Jana, Somnath
Kim, Kwangho
Sulikowski, Gary
ICs
NCI
NCATS
Leidos
FDA
Applications
Therapeutics
Therapeutic Areas
Oncology
This technology includes LDHA inhibitors that have been synthesized and tested for the treatment of glycolytic cancers. These compounds may have improved activity over previous compounds.
Commercial Applications
Further clinical work could establish these small molecule inhibitors of LDHA as a first-in-class/target therapy in oncology with a specific focus on glycolytic cancers.
Competitive Advantages
Currently there are no known high-quality inhibitors with demonstrated in vivo activity. These compounds are more potent than these prior art compound and have the potential for demonstrated in vivo activity as well.
Licensing Contact: